A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy
β Scribed by Dr. Joan M. Bull; Douglass C. Tormey; Shou-Hua Li; Paul P. Carbone; Geoffrey Falkson; Johannes Blom; Elliot Perlin; Richard Simon
- Publisher
- John Wiley and Sons
- Year
- 1978
- Tongue
- English
- Weight
- 551 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
A prospective randomized trial was conducted comparing the clinical response of 78 previously untreated patients with advanced metastatic breast cancer to a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or to a combination of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF). Sixty-two percent of the patients receiving CMF responded to treatment compared to an 82% response rate for the patients receiving CAF. Although within acceptable limits, hematologic and GI toxicity was greater with CAF. There was no significant difference in the duration of response to the two regimens. Therefore, the therapeutic difference between the two therapies is a higher initial response rate to the adriamycin containing regimen.
π SIMILAR VOLUMES
## Abstract ## Objective To compare the benefits of initiating treatment with methotrexate (MTX) and infliximab (antiβtumor necrosis factor Ξ± [antiβTNFΞ±] monoclonal antibody) with those of MTX treatment alone in patients with rheumatoid arthritis (RA) of β€3 years' duration. ## Methods RA patient
From September 1982 to December 1985, 59 previously untreated patients with Stage II squamous cell carcinoma of the thoracic esophagus were randomly assigned to receive radiation therapy (RT) alone versus the concomitant use of RT and chemotherapy (CT) with 5-fluorouracil (5-FU), mitomycin C, and bl